Clinical implications of a possible role of vitamin D in multiple sclerosis
- 1.9k Downloads
Hypovitaminosis D is currently one of the most studied environmental risk factors for multiple sclerosis (MS) and is potentially the most promising in terms of new clinical implications. These practical consequences, which could be applied to MS patients without further delay, constitute the main purpose of this review. Vitamin D is involved in a number of important general actions, which were not even suspected until quite recently. In particular, this vitamin could play an immunomodulatory role in the central nervous system. Many and varied arguments support a significant role for vitamin D in MS. In animal studies, vitamin D prevents and improves experimental autoimmune encephalomyelitis. Epidemiologically, latitude, past exposure to sun and the serum level of vitamin D influence the risk of MS, with, furthermore, significant links existing between these different factors. Clinically, most MS patients have low serum levels of vitamin D and are in a state of insufficiency or even deficiency compared to the international norm, which has been established on a metabolic basis. Large therapeutic trials using vitamin D are still lacking but the first results of phase I/II studies are promising. In the meantime, while awaiting the results of future therapeutic trials, it can no longer be ignored that many MS patients have a lack of vitamin D, which could be detected by a serum titration and corrected using an appropriate vitamin D supplementation in order to restore their serum level to within the normal range. From a purely medical point of view, vitamin D supplementation appears in this light to be unavoidable in order to improve the general state of these patients. Furthermore, it cannot currently be ruled out that this supplementation could also be neurologically beneficial.
KeywordsMultiple sclerosis Vitamin D
Risk factors for MS are becoming clearer even if the mechanisms leading from these risk factors to the disease itself remain obscure. There are two main types of risk factors for MS, i.e. genetic and environmental, likely with complex interactions between them and effects which may be deleterious or protective, depending on the case . Genetic risk factors are numerous [56, 99], but they are still relatively not well known and will not be dealt with here. Three environmental risk factors have recently emerged from the literature [5, 6, 7, 34, 54, 62, 92, 93]—i.e. hypovitaminosis D, past infection with Epstein-Barr virus (EBV) and smoking—with effects that could be cumulative [46, 53]. In this review, we shall confine our analysis to hypovitaminosis D, which is the risk factor currently the most promising in terms of immediate clinical implications.
Physiological and metabolic basis
Vitamin D is a steroidal hormone metabolised successively in the skin (by sunlight or ultraviolet B rays), the liver and the kidneys to the active metabolite 1.25-dihydroxyvitamin D3 (calcitriol), which has a half life of several hours. This metabolite is recognised by tissues containing specific vitamin D receptors which are present in many parts of the body: skin, bone, muscles, gonads, intestine, central nervous system (CNS), microglia, activated monocytes and B and T lymphocytes [23, 49, 50, 51, 69]. In addition to its well known action on calcium and phosphorus metabolism, vitamin D seems to have other important general effects, in particular anti-inflammatory and antiproliferative, and also modulatory effects on neurotrophins, growth factors and neurotransmitters in the CNS of mammals. Daily vitamin D requirements have recently been re-evaluated and are at least 2,000 IU/d, which is far higher than was thought necessary up until a few years ago [47, 52, 126, 127]. Vitamin D intake via (non-enriched) food is marginal in western diets, generally providing less than 100 IU/d, which is far below the daily requirement, and even Scandinavian diets (rich in oily fish) scarcely exceed a few hundred IU/d . Sunshine therefore remains the principal natural source of vitamin D, providing approximately 90% of requirements. Although sunbathing can provide 10,000–20,000 IU in 15–30 min, this supply disappears within a few weeks and cannot readily be replenished throughout the year except in tropical countries [52, 127]. Moreover, the elderly, regardless of origin, and dark-skinned subjects, regardless of age, are less able to synthesise vitamin D than young, light-skinned subjects, who, if they protect themselves too much from the sun (by clothing or a sun block) may also rapidly find themselves in a state of vitamin D insufficiency. Lastly, women generally have lower serum levels than men [132, 133] and when pregnant or breast-feeding their vitamin D requirement is higher, which is, at the current time, rarely compensated for [23, 130].
The serum component of vitamin D usually measured is 25-hydroxyvitamin D (with a half life of several weeks), which is representative of an individual’s overall vitamin D status [107, 134, 135]. The official international standard for serum 25-hydroxyvitamin D levels has been established on a physiological basis, mainly from calcium metabolism, since it is difficult to use control groups in the general population of temperate countries where most people could in fact be in a state of vitamin D insufficiency in the absolute, in particular in winter (see below). The internationally accepted norms fall between 75 and 200 nmol/l, with insufficiency existing below 75 nmol/l and deficiency below 25 nmol/l [10, 25, 38, 52, 69, 96, 107, 125, 135]. The 75 nmol/l lower limit has not been arbitrarily established: it corresponds to the serum level below which the parathyroid hormone is stimulated by the lack of vitamin D and below which osteoporosis and pathological fractures become frequent. In fact, the current usual recommendations [38, 48, 52, 88, 107, 128, 135] suggest that a blood level of at least 90 or 100 nmol/l is needed first to optimise calcium and phosphorus metabolism (to reduce osteoporosis and to protect against pathological fractures), but also to improve the prevention of several major autoimmune diseases (diabetes, MS, lupus, rheumatoid arthritis etc.), three major cancers (colon, breast, prostate) and other common syndromes (asthenia, depression, hypertension) and infections in general, all of which are pathologies in which there has recently been an upsurge of studies implicating vitamin D. On these physiological grounds it can be deduced that vitamin D is most likely involved in a number of general regulatory activities, over and above calcium and phosphorus metabolism, and could have a notable immunological role to play, in particular within the CNS. One might also suspect that a vitamin D insufficiency or deficiency could exist whenever there is a shortage of sunlight, whether for an entire population—deprived of sunshine for reasons of climate—or for a given individual spending little or no time in the sun.
Experimental and immunological studies
There is a long-standing body of experimental evidence—constantly being added to and now quite extensive—in favour of vitamin D having a marked role in experimental autoimmune encephalitis (EAE). Furthermore, many recent immunological studies suggest that this role could be anti-inflammatory and immunomodulatory. Vitamin D clearly prevents the induction of EAE if administered before the triggering of the disease and noticeably improves clinical signs in affected mice if it is administered afterwards, thus having a significant effect that is both protective and curative[9, 11, 14, 15, 17, 19, 32, 67, 78, 79, 82, 84, 85, 86, 90, 102, 108, 110, 121]. This action is reported to be more marked in female mice than in male mice, due to the potentialisation of vitamin D by oestrogen . It should be noted that a potentialisation of this type has also been reported in non-menopausal women [113, 123]. In EAE, vitamin D could have an anti-inflammatory effect  by reducing macrophages  and/or by regulating certain cytokines [18, 90, 110], and/or a protective effect on myelin by activating oligodendrocytes  and/or an immunomodulatory effect on T lymphocytes by inhibiting Th1 development and increasing Th 2 and Tr (regulatory T) lymphocyte restoration [14, 16, 77, 82, 102]. The latter effect (while not ruling out the others) currently seems the most well-founded, with vitamin D consequently having a mode of action that might be close to that of interferon β, the beneficial effect of which in EAE is indeed potentiated by vitamin D . Lastly, in patients with MS, it has recently been suggested that vitamin D also has a beneficial effect on Tr lymphocytes [24, 97]. Even if EAE is not exactly the same as MS, all these results, taken together, constitute a solid experimental basis that supports the existence of a marked immunological effect of vitamin D in this pathological field.
Effect of latitude on the prevalence of MS
Latitude has an undisputed effect on the prevalence of MS, which increases with distance from the equator, in both the northern and southern hemispheres, at a world level , at a continental level, as in Europe [65, 91], as well as in very large countries, such as the USA  and Australia , and even in smaller countries, such as New Zealand  or France [30, 129]. In contrast, very low prevalences of MS are observed in tropical regions, for example in Ecuador , even though the protective effect of such regions appears to be nowadays slightly attenuated, likely due to changes in life style . One can also see—at comparable latitudes—that the degree of sunlight in a given region or type of habitat (e.g., in Switzerland, in the mountains compared to lowland areas) is correlated with the prevalence of MS [64, 116, 119, 120]. It should also be noted that emigration after the age of 15–20 years has varying effects on immigrants depending on the direction of emigration: if it is from a region with a high prevalence of MS to a region of low prevalence, immigrants tend to acquire the low prevalence of the region to which they have emigrated (thereby losing the high risk of their region of origin), whereas in the opposite direction, when they move from a region with a low prevalence of MS to a region of high prevalence, they retain the low risk of their region of origin, at least for themselves, but not for their children, in whom one observes the same prevalence as that of the inhabitants of their host region [27, 28, 29, 31, 41, 66]. Only environmental (non-genetic) risk factors can explain these differences in prevalence between the new immigrants and their children. As for the difference in effect on the prevalence of MS according to the direction of emigration, this could be due to protective environmental factors of countries with a low prevalence of MS, which also happen to be those with (a) the most sun but also (b) the least ‘hygiene’ in its broadest sense, due to (1a) the sustained protective action of past exposure to sunlight (see below) received in these countries during childhood, which could persist after emigration to a country with less sun, and/or (1b) a subsequent, relatively protective effect of diverse infections contracted during childhood in countries with a low prevalence of MS (the so-called ‘hygiene hypothesis’), and (2) the permanent and immediate protective effect of a country with a sunny climate if one has moved there before the normal age of onset of MS (i.e. in young adults) [5, 6, 7]. In sum, even if the effects of migration make it a little more difficult to interpret the role of latitude in MS risk, they do make it possible to suspect the involvement of several environmental risk factors—possibly including infectious factors—to explain these effects.
Effect of latitude on serum vitamin D levels in the general population
At this point in the discussion, it is appropriate to analyse the effects of latitude on vitamin D status in the general population. Numerous studies have shown that on average vitamin D levels are too low—in other words below the normal range, which has been established on a metabolic basis (see above)—in the adult population of all temperate countries where they have been studied: for example, in the USA, 74 nmol/l in a cohort from 1988 to 1994 (n = 15,000)  declining to 60 nmol/l in a cohort from 2000 to 2004 (n = 18,558) [33, 71]; between 75 and 51 nmol/l in Australia, depending on the region (n = 1,398) ; 51 nmol/l in the United Kingdom (n = 7,437), with a north-south gradient ; 49 nmol/l in New Zealand (n = 2,900) ; 61 nmol/l in southern Canada (n = 188) ; and 61 nmol/l in France (n = 1,579) . It should be noted that the serum levels were determined in different seasons of the year in four of these studies and that on each occasion the levels in winter were 20–30 nmol/l lower than those in summer (Australia, United Kingdom, New Zealand and Canada). In France, the study related to nine different regions during the winter of 1994–1995. The lowest serum levels were observed in the north (43 nmol/l) and north-east (53 nmol/l) and the highest in the south (81 nmol/l) and south-west (94 nmol/l), with significant correlations existing between these levels and both latitude (P < 0.01) and amount of sunshine (P = 0.003) . In all these temperate countries, it was emphasised that such very low average levels of vitamin D raise serious public health issues and that there is an urgent need for national heath authorities to take preventive measures [38, 39], leading for example to vitamin D supplementation for all subjects in a state of insufficiency . It should also be noted that rickets in very young children and osteomalacia in the elderly are nowadays generally well prevented in developed countries by paediatricians and geriatricians, who preventively treat their patients quasi systematically with vitamin D, whereas, between these two extremities of life, little interest is shown in the vitamin D status of older children, adolescents and adults, probably on the assumption that in the great majority of cases it is normal; in fact, all recent epidemiological studies performed in medium or high latitude countries have shown that this is not at all the case (see above), which is potentially prejudicial for all people in these age-groups, not protected from hypovitaminosis D and its consequences in terms of increased risk of multiple, serious general affections, possibly including MS.
Effect of exposure to sunlight on the risk of MS
Based on a study of 136 MS patients and 272 control subjects in Tasmania, the risk of MS was found to be lower in those who in their childhood had been exposed to sunlight during their holidays and weekends than in those who had not benefited from such exposure (P < 0.01), a finding that was also correlated with the degree of actinic damage to their skin (an indicator of cumulative sun exposure, measured on the back of the hand) (P < 0.01) . A similar result was found for the risk of CIS in Australia, which was correlated with past exposure to sun, actinic damage and latitude . Inverse correlations between the risk of MS and past exposure to sunlight have also been reported in the USA , Norway  Canada  and Australia , with, furthermore, probable genetic regulation in the latter case. Lastly, in the USA, based on 79 monozygotic pairs of twins, one in each pair having MS and the other not and both twins being different in terms of exposure to the sun during their childhood (assessed on the basis of nine different activities implying sun exposure), it was shown that the twins who did not have MS were also those who had had significantly higher past exposure to the sun . This result is particularly important because each pair of twins had the same genetic material and, apart from exposure to the sun, identical environmental constants (residence, food, etc.). In sum, the level of past exposure to the sun does indeed seem to play a role in the risk of MS.
Effect of the serum vitamin D level in the general population on the risk of MS
To date, only one study has directly analysed the risk of MS based on the serum level of 25-hydroxyvitamin D in normal subjects before MS occurred in some of them. The study, which appears methodologically sound, is therefore extremely important since it now indicates a direct link between the level of vitamin D circulating in the blood and the disease, without having to rely on the effect of latitude or sun exposure . The study included 257 cases of MS that occurred in young American soldiers (148 white and 77 black), and 514 control subjects, who had given at least one serum sample before the onset of any neurological symptoms during their military service. For the white subjects, 5 subgroups were defined according to the serum level of vitamin D: the subgroup with the highest—in fact normal—levels of vitamin D (between 99 and 152 nmol/l) had a significantly lower risk of MS than the subgroup with the lowest levels (between 15 and 63 nmol/l) (P < 0.01); for the less numerous black subjects, the results were not significant between the three defined subgroups, but the serum levels were much lower (not exceeding 99 nmol/l) with, therefore, a much smaller range of serum levels between the different subgroups than for the white subjects. It was concluded in this study that a relatively high serum vitamin D level (though still within the normal range) is associated with a lower risk of MS in white subjects. On the basis of this study, Ascherio and Munger  have estimated that almost three-quarters of MS cases might be avoided if the serum levels of vitamin D were maintained above 100 nmol/l during childhood and adolescence in the general population. Furthermore, the fact that there is a correlation between the mean levels of vitamin D in the general population in regions of France and the prevalence of MS in these regions (Fig. 3) establishes an additional link between serum vitamin D level and the risk of MS. Lastly, we must also cite studies where the supposed high oral intake of vitamin D, in the form of oily fish [58, 59] or vitamin supplements , decreased the risk of MS. The overall conclusion of these epidemiological studies is that it seems at least possible and already likely (see above) that there are links of causality between latitude, exposure to sun, serum vitamin D level and the risk of MS, in other words that the last link in this chain of influences, i.e. the one that is essential since it directly relates the organism to variations in the external environment, is vitamin D. This point of view, already proposed more than 35 years ago , now appears to be supported by numerous convergent experimental and epidemiological findings.
Clinical studies on vitamin D in patients with MS have not yet achieved the same level of statistical power as experimental and epidemiological studies, but they are beginning to accumulate and, in the great majority of cases, their results are along the same lines, namely that vitamin D has a probable role in MS.
Biological studies related to vitamin D in MS
Effect of vitamin D treatment in MS
Studies on the use of vitamin D in MS are still rare and limited in scope. After a two-year course of treatment with vitamin D (5,000 IU/d in the form of cod liver oil), 10 patients with MS had a 60% reduction in the predicted number of relapses, but there was no control group . In another uncontrolled study, 15 patients who received 100 IU/d for 48 weeks experienced a 50% reduction in relapses . In a study on 39 patients with MS (17 treated with 1,000 IU/d of vitamin D3 (cholecalciferol) for 6 months and 22 control subjects), the treated patients had a significantly increased level of TGF-β1, an anti-inflammatory cytokine affected by vitamin D in EAE . Lastly, a Canadian team recently demonstrated that the use of high doses of vitamin D3 (cholecalciferol, 14,000 IU/d) during a long period (6 months–1 year) did not induce hypercalcaemia or notable side-effects, despite serum vitamin D levels of nearly 400 nmol/l . After 1 year of such treatment, a 41% reduction in the number of relapses and a significant improvement in EDSS was observed in the treated patients (n = 25 vs. 24 untreated patients) . The results of these methodologically weak studies do not of course allow us to draw any definite conclusions. However, taking into account the full scientific context, they are encouraging and provide ample justification for much more extensive therapeutic trials (phase II or phase III). The appropriate vitamin D doses will, however, have to be determined, since the daily dosages in the aforementioned four studies were 100, 1000, 5,000 and 14,000 IU/d, a situation that raises the perplexing question of the useful therapeutic dosage.
Questions and practical clinical approach to vitamin D in MS
While awaiting the results of future large-scale therapeutic studies using vitamin D, which will take several years to complete, we can already put forward several questions on the subject of vitamin D in MS (Fig. 1). Does vitamin D have a protective role in MS? We can either reply straight away in the affirmative if we consider that the physiological and experimental arguments and the epidemiological studies have already provided a sufficient level of probability, or we can, rather, remain skeptical and wait for other, more convincing studies. Yet, a negative response to such a question would appear to be untenable in the light of the data already available. Does vitamin D have a role to play in influencing the progression of MS once the disease has started? The answer to this second question depends on the results of the clinical studies already undertaken in MS, which are still limited as regards serum vitamin D levels and remain in the embryonic state in terms of therapeutic applications. Consequently, if at present we do not wish to reply to this question in either the affirmative or the negative, we can remain in a state of expectation. However, the first two questions lead inevitably to a third question. Should the serum level in vitamin D of patients with MS be systematically tested? If the answer to the first two questions was not in the negative, the answer to this third question must inevitably be in the affirmative. In fact, it is no longer the specifically neurological—and still uncertain—aspect of these questions that is being raised here but rather a general and already far better documented medical issue. Indeed, multiple studies—even if we only take into account those that have actually been published—suggest that a majority of patients with MS have a vitamin D insufficiency, a good number of whom are even in a state of deficiency. Moreover, this insufficiency could be even slightly more marked than that already existing in the general population. From a purely medical point of view, we cannot ignore that a vitamin insufficiency or deficiency existing in the absolute is, at the very least, detrimental to the general health of these patients. This point should be considered by itself right now and uncoupled both from any possible, additional specific neurological aspects and from the more global problem of hypovitaminosis D existing in the general population, both questions which should and will be dealt with separately in the immediate future.
After the serum titration of vitamin D, it appears useful to supplement patients who are in a state of insufficiency . This should involve MS patients at all stages of the disease, but could also include patients who are at the CIS stage or even before this stage (i.e. with ‘pre-CIS’, based solely on magnetic resonance imaging criteria), in an attempt also to achieve maximal possible protection of patients who are still at the very beginning of an abnormal inflammatory process. However, for all these patients with a lack of vitamin D, the main aim of supplementation would, at present, be a general medical one, namely simply to increase serum concentrations to the currently recommended normal level, i.e. in the region of 100 nmol/l (see above): this would mean administering between 1,000 and 3,000 IU of vitamin D3 (cholecalciferol) on average per day (using either daily or monthly intakes), adjusted according to the initial serum concentration [47, 52, 107, 124, 126, 128]. This measure should already improve the general health of patients with vitamin D insufficiency or deficiency by normalising calcium and phosphorus metabolism, but perhaps also by reducing asthenia, optimising muscle strength, reducing susceptibility to various infections, having a beneficial effect on thymic status, etc. Furthermore, it cannot currently be ruled out that relatively moderate doses of vitamin D—precisely such as those used to bring the serum level up to normality—can also have a favourable effect on the progression of the neurological disease itself, including at its earliest stages (CIS and pre-CIS). Lastly, it is important before starting the treatment to check that there is no hypercalcaemia (which may exceptionally be present) and after several months to monitor the serum vitamin D level and calcaemia, so that the daily dosage can be adjusted if necessary. There is no need to fear vitamin D intoxication—an unfounded myth—or hypercalcaemia during the treatment (1) if the patient has normal (or low) calcaemia before starting the treatment, (2) if one uses 25-hydroxyvitamin D3 (cholecalciferol) and not 1,25-dihydroxyvitamin D3 (calcitriol), with, moreover, (3) doses of less than 10,000 IU/d [43, 124, 127]. This theoretical upper limit (10,000 IU/d) leaves a considerable safety margin if one uses at most a dose of 2,000 or 3,000 IU/d simply to normalise serum concentrations. Very long-term vitamin D treatment should be envisaged and, where low exposure to sunlight is a constant factor, maintained generally at the same doses, failing which the serum concentration will return to the insufficiency zone if the treatment is stopped or the dosage simply reduced. In sum, this treatment, which has become mandatory from a general medical point of view for MS patients with a proven lack of vitamin D, can be given in addition to the other, main preventive therapies and is in fact simple, natural, safe and inexpensive. It could also be useful from a neurological perspective, for the overall progression of MS and for certain everyday symptoms.
Based on considerable physiological evidence, a large body of experimental findings, consistent epidemiological data and limited but promising clinical studies, the hypothesis that hypovitaminosis D is one of the environmental risk factors for MS has rapidly gained support and could soon be confirmed by more extensive clinical studies. Over and above its possible role in MS, hypovitaminosis D—due to its widespread distribution among the general population in countries with low levels of sunlight—now raises a crucial public health problem which must be solved if we are to achieve optimal prevention of a number of general affections that are common in these countries. Neurologists, like all medical practitioners, should be keenly aware of this problem, but those who are more particularly involved in caring for MS patients must be doubly receptive and rapidly preventive, since ‘time is brain’ is also applicable to MS.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
- 1.Abad EP, Pérez M, Alarcon T, Castro E, Diaz F, Santibanez R (2008) Epidemiological evidence of multiple sclerosis in Ecuador. Mult Scler 14(Suppl 1):S55–S56Google Scholar
- 8.Barnes M, Bonham MP, Robson PJ, Strain JJ, Lowe-Strong AS, Eaton-Evans J et al (2007) Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult Scler 13:670–672. doi: 10.1177/1352458506072666 PubMedCrossRefGoogle Scholar
- 13.Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Thibault L et al (2008) A phase I/II dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis. Mult Scler 14(Suppl 1):S34Google Scholar
- 16.Cantorna MT, Mahon BD (2004) Mounting evidence for vitamin D as an environmental factor affecting autoimmune prevalence. Exp Biol Med 229:1136–1142Google Scholar
- 24.Correale J, Ysrraelit MC, Gaitan MI (2009) Immunomodulatory effects of 1,25-dihydroxyvitamin D3 in multiple sclerosis. Brain [Epub ahead of print]Google Scholar
- 30.Fromont A, Adnet J, Clerc L, Bonithon Kopp C, Binquet C, Moreau T (2008) The French prevalence gradient of multiple sclerosis according to gender. Mult Scler 14(Suppl 1):S65Google Scholar
- 39.Grant WB, Cross HS, Garland CF, Gohram ED, Moan J, Peterlik L et al (2009) Estimated benefit of increased vitamin D status in reducing the economic burden of disease in Western Europe. Prog Biophys Mol Biol [Epub ahead of print]Google Scholar
- 45.Hayes CE, Cantorna MT, De Luca HF (1997) Vitamin D and multiple sclerosis. Proc Soc Biol Med 216:21–27Google Scholar
- 56.International Multiple Sclerosis Genetics Consortium (2008) The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun 10(1):11–14Google Scholar
- 72.Lucas R, Taylor BV, Ponsonby A-L, Chapman P, Coulthard A, Dear K et al (2008) Latitudinal variation in incidence of first demyelinating events: descriptive analyses of case participants in the Ausimmune Study. Mult Scler 14(Suppl 1):S190–S191Google Scholar
- 74.Makhani N, Magalaes S, Fairbrother C, Banwell B (2008) Vitamin D status in children with multiple sclerosis. Mult Scler 14(Suppl 1):S191Google Scholar
- 77.Mattner FS, Smiroldo S, Gabliati F, Muller M, Di Lucia P, Poliani PL et al (2000) Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D3. Eur J Neuroimmunol 30:498–508. doi: 10.1002/1521-4141(200002)30:2<498::AID-IMMU498>3.0.CO;2-Q CrossRefGoogle Scholar
- 94.Ramagopalan SG, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA et al (2009) Expression of multiple sclerosis-associated MHC class II Allele HLA-DBR1*1501 is regulated by vitamin D. PLoS Genet 5:e1000369. doi: 10.1371/journal.pgen.1000369
- 97.Royal W, Mia Y, Li H (2008) Vitamins D and A levels and regularity T cells in patients with multiple sclerosis. Mult Scler 14(Suppl 1):S242Google Scholar
- 106.Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna J-P, Lillius E-M, Mononen I (2008) A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 79:152–157. doi: 10.1136/jnnp.2006.105320 PubMedCrossRefGoogle Scholar
- 109.Spach KM, Pedersen LB, Nashold FE, Kayo T, Yandell BS, Prolla TA, Hayes CE (2004) Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol Genomics 18:141–151. doi: 10.1152/physiolgenomics.00003.2004 PubMedCrossRefGoogle Scholar
- 112.Taylor BV, Richardson A, Mason DF, Wlloughby E, Abenethy D, Sabel C (2008) Prevalence of multiple sclerosis in New Zealand. Mult Scler 14(Suppl 1):S202Google Scholar
- 113.Tjellesen L, Christiansen C, Hummer L, Larsen NE (1983) Unchanged biochemical indices of bone turnover despite fluctuations in 1,25-dihydroxyvitamin D during the menstrual cycle. Acta Endocrinol (Copenh) 102:476–480Google Scholar
- 121.Van Etten E, Branisteanu DD, Overberg L, Bouillon R, Verstuyf A, Mathieu C et al (2003) Combination of a 1,25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 32:397–404. doi: 10.1016/S8756-3282(03)00030-9 PubMedCrossRefGoogle Scholar
- 133.Zadshir A, Tareen N, Pan D, Norris K, Martins D (2005) The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis 15:S5 97–101Google Scholar